You are here:
09 February 2021 / deal

Morgan Stanley, BofA Securities, and SVB Leerink act as joint book-running managers in connection with the IPO of Pharvaris on NASDAQ

Loyens & Loeff N.V. trad op als Nederlandse counsel voor Morgan Stanley, BofA Securities, en SVB Leerink, die optraden als joint book-running managers van de aanbieding. Oppenheimer & Co. en Kempen & Co traden op als co-managers.

Pharvaris N.V. (“Pharvaris”), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies, including novel, small molecule bradykinin-B2-receptor antagonists for the treatment of hereditary angioedema (HAE) and other bradykinin-B2-receptor-mediated indications, on 4 February 2021 announced the pricing of its upsized initial public offering of 8,270,500 of its ordinary shares at an initial public offering price of $20.00 per share, for total gross proceeds of approximately $165.4 million.

In addition, Pharvaris has granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,240,575 ordinary shares at the public offering price less underwriting discounts and commissions. This over-allotment option was exercised on 5 February 2021 in full. The ordinary shares are expected to begin trading on the Nasdaq Global Select Market on 8 February 2021 under the symbol "PHVS."


New FDI screening mechanisms in the Netherlands

The Netherlands recently introduced two FDI screening mechanisms that will have significant impact on the transaction practice... read more

Shareholder activism: Minority rights and shareholder lawsuits

Changes to minority rights and shareholder lawsuits potentially affecting shareholder activism in Switzerland in the future. read more

Legislative proposal on a more balanced men-women ratio adopted

On 28 September 2021, a legislative proposal to improve the men-women ratio in boards was adopted by the Dutch Senate. read more